此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Guselkumab 和白细胞介素 17 (IL-17) 抑制剂治疗常规临床实践中银屑病关节炎患者的研究 (PsABIOnd)

2026年11月2日 更新者:Janssen Pharmaceutica N.V., Belgium

在常规临床实践中评估 Guselkumab (Tremfya) 和 IL-17 抑制剂治疗银屑病关节炎患者;一项前瞻性观察性队列研究

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

研究概览

地位

主动,不招人

详细说明

Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.

研究类型

观察性的

注册 (实际的)

1314

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Kemerovo、俄罗斯、G4 0SF
        • SBEU HPE Kemerovo State Medical Academy
      • Moscow、俄罗斯、121552
        • Bakoulev Scientific Center For Cardiovascular Surgery Rams
      • Moscow、俄罗斯、190068
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Tomsk、俄罗斯、634045
        • City Hospital #3
    • British Columbia
      • Vancouver、British Columbia、加拿大、V5Z 1J9
        • Artus Health Centre
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R3A 1M3
        • Manitoba Clinic
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、加拿大、A1C 5B8
        • St. Claire's Mercy Hospital - Rheumatology Research
    • Nova Scotia
      • Coxheath、Nova Scotia、加拿大、B1L 1B3
        • Dr. Juris Lazovskis Incorporated
    • Ontario
      • Dundas、Ontario、加拿大、L9H 1B7
        • Private Practice - Dr. Pauline Boulos
      • Markham、Ontario、加拿大、L3R 2C7
        • Markham Rheumatology Hub
      • Mississauga、Ontario、加拿大、L5A 3V8
        • Brandusa Florica Medicine Professional Corporation
      • Orillia、Ontario、加拿大、L3V 1T5
        • The Waterside Clinic
      • Ottawa、Ontario、加拿大、K1H 7W9
        • The Ottawa Hospital Research Institute
      • Windsor、Ontario、加拿大、N8X 1T3
        • Dr Sabeen Anwar Medicine Professional Corporation
    • Quebec
      • Montreal、Quebec、加拿大、H1T 2M4
        • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
      • Québec、Quebec、加拿大、G1V 4K5
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Rimouski、Quebec、加拿大、G5L 5T1
        • Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
      • Trois-Rivières、Quebec、加拿大、G9A 3X2
        • Centre de Recherche Musculo Squelettique
    • Saskatchewan
      • Saskatoon、Saskatchewan、加拿大、S7K 0H6
        • Community Rheumatology Care
      • Saskatoon、Saskatchewan、加拿大、S7K 0H6
        • Rheumatology Associates of Saskatoon
      • Kaohsiung City、台湾、81362
        • Kaohsiung Veterans General Hospital
      • Kaohsiung City、台湾、83301
        • Chang Gung Medical Foundation
      • Taichung、台湾
        • Taichung Veterans General Hospital
      • Bogotá、哥伦比亚
        • BIOMAB
      • Bucaramanga、哥伦比亚
        • Servimed S A S
      • Medellín、哥伦比亚、50012
        • Clinisalud del Sur
      • Medellín、哥伦比亚、50025
        • Clinica Vascular las Americas
      • Montería、哥伦比亚、230002
        • Funcentra
      • Mérida、墨西哥、97070
        • Medical Care & Research SA de CV
      • México、墨西哥、07760
        • Consultorio de Reumatologia
      • Zapopan、墨西哥、45116
        • Hospital Puerta de Hierro
      • Graz、奥地利、8036
        • LKH-Univ. Klinikum Graz
      • Linz、奥地利、4021
        • Kepler Universitatsklinikum GmbH
      • Vienna、奥地利、1090
        • Medizinische Universitaet Wien
      • Vienna、奥地利、A-1100
        • Evang. Krankenhaus Gemein. Betriebgesm. Mbh
      • Athens、希腊、10676
        • Evangelismos General Hospital of Athens
      • Athens、希腊、11527
        • Laiko General Hospital of Athens
      • Athens、希腊、11521
        • Athens Navy Hospital
      • Athens、希腊、11527
        • General Hospital 'Gennimatas'
      • Athens、希腊、11527
        • Hippokration General Hospital of Athens, B' Internal Medicine Clinic,
      • Ioannina、希腊、45560
        • University Hospital of Ioannina
      • Pátrai、希腊、263 32
        • 'Agios Andreas' General Hospital of Patras
      • Pátrai、希腊、26500
        • University General Hospital of Rio Patras
      • Thessaloniki、希腊、546 42
        • Ippokrateio Hospital
      • Amberg、德国、92224
        • Praxis für Rheumatologie
      • Bayreuth、德国、95444
        • Rheuma-Praxis Bayreuth
      • Berlin、德国、12161
        • Rheumatologische Schwerpunktpraxis
      • Berlin、德国、13055
        • Rheumatologische Schwerpunktpraxis 1
      • Cologne、德国、51149
        • Krankenhaus Porz am Rhein
      • Düsseldorf、德国、40225
        • Universitatsklinikum Dusseldorf
      • Erfurt、德国、99096
        • Service Rheuma Erfurt
      • Frankfurt、德国、60590
        • Universitatsklinikum Frankfurt
      • Halle、德国、6128
        • Rheumapraxis Dr. Liebhaber
      • Hamburg、德国、22767
        • Rheumatologie im Struenseehaus
      • Hamburg、德国、22415
        • Praxis fur Klinische Studien und Praxis fur Orthopadie
      • Herne、德国、44649
        • Rheumazentrum Ruhrgebiet
      • Leipzig、德国、04109
        • Rheumatologische Praxis 1
      • Magdeburg、德国、39104
        • Rheumatologische Praxis
      • München、德国、81541
        • Praxiszentrum St. Bonifatius
      • Neubrandenburg、德国、17033
        • Praxis Thilo Klopsch
      • Püttlingen、德国、66346
        • Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie
      • Ratingen、德国、40878
        • Rheumazentrum Ratingen
      • Templin、德国、17268
        • Rheumatologisch-immunologische Arztpraxis
      • Vogelsang-Gommern、德国、39245
        • Immunologisches Zentrum Vogelsang-Gommern GmbH
      • Bari、意大利、70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
      • Campobasso、意大利、86100
        • Ospedale Regionale Cardarelli-Università degli Studi del Mol
      • Catanzaro、意大利、88100
        • Universita della Magna grecia
      • Florence、意大利、50141
        • AOU Careggi
      • Naples、意大利、80131
        • Azienda Ospedaliera Universitaria Federico II
      • Naples、意大利、80131
        • Seconda Univesità degli Studi di Napoli, AOU
      • Palermo、意大利、90127
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Pisa、意大利、56126
        • Azienda Ospedaliero Universitaria Pisana
      • Potenza、意大利、85100
        • Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale
      • Rome、意大利、20123
        • Universita Cattolica del Sacro Cuore
      • Rozzano、意大利、20156
        • Istituto Clinico Humanitas
      • Torino、意大利、10126
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino
      • Udine、意大利、33100
        • Azienda Ospedaliero Universitaria S.Maria Della Misericordia
      • Verona、意大利、37067
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Hyōgo、日本、6751392
        • Kita-harima Medical Center
      • Meguro-ku、日本、153-8515
        • Toho University Medical Center, Ohashi Hospital
      • Osaka、日本、550 0006
        • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
      • Osaka、日本、545 8586
        • Osaka Metropolitan University Hospital
      • Sapporo、日本、060-8648
        • Hokkaido University Hospital
      • Tokyo、日本、181 8611
        • Kyorin University Hospital
      • Bruges、比利时、8000
        • AZ Sint-Jan
      • Brussels、比利时、1070
        • Hopital Erasme
      • Genk、比利时、3600
        • Reumaclinic Genk-Hasselt
      • Leuven、比利时、3000
        • UZ Leuven
      • Liège、比利时、4000
        • CHU de Liège - Domaine Universitaire du Sart Tilman
      • Bobigny、法国、93000
        • Hôpital Avicenne
      • Cholet、法国、49300
        • Centre Hospitalier de Cholet
      • Clermont-Ferrand、法国、63003
        • Hôpital Gabriel Montpied
      • Créteil、法国、94000
        • Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor
      • Lille、法国、59037
        • CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur
      • Lyon、法国、69008
        • Centre Orthopedique Santy
      • Lyon、法国、69300
        • Clinique de l'Infirmerie Protestante de Lyon
      • Nice、法国、6006
        • Hôpital Saint Roch
      • Orléans、法国、45032
        • CHR Orléans - Nouvel Hôpital Orléans La Source
      • Paris、法国、75018
        • Hôpital Bichat
      • Paris、法国、75010
        • Hôpital Lariboisière - Centre Viggo Petersen
      • Paris、法国、75012
        • Hopital Saint-Antoine
      • Paris、法国、75651
        • Hopital Pitie Salpetriere
      • Strasbourg、法国、67098
        • CHRU Hôpital de Hautepierre
      • Toulouse、法国、31059
        • Hopital Purpan
      • Échirolles、法国、38130
        • CHU Grenoble
      • Adelaide、澳大利亚、5011
        • The Queen Elizabeth Hospital
      • Footscray、澳大利亚
        • Footscray Hospital, Western Health
      • St Leonards、澳大利亚、2065
        • Royal North Shore Hospital
      • Gothenburg、瑞典、41345
        • Sahlgrenska Universitetssjukhuset
      • Malmö、瑞典、20502
        • Universitetssjukhuset i Lund
      • Stockholm、瑞典、113 65
        • Akademiskt Specialistcentrum centrum för reumatologi
      • Uppsala、瑞典、75185
        • Akademiska Sjukhuset
      • Örebro、瑞典、70185
        • Universitetssjukhuset Orebro
      • Fribourg、瑞士、1708
        • HFR Fribourg - Hôpital Cantonal
      • Aberdeen、英国、AB25 2ZB
        • NHS Grampian - Aberdeen Royal Infirmary (ARI)
      • Abergavenny、英国、NP7 7EG
        • Nevill Hall Hospital
      • Airdrie、英国、ML6 0JS
        • University Hospital Monklands
      • Barnet、英国、EN5 3DJ
        • Royal Free London NHS Foundation Trust Barnet Hospital
      • Bath、英国、BA1 3NG
        • Wolfson Centre Royal United Hospitals
      • Glasgow、英国、650029
        • Glasgow Royal Infirmary
      • Hull、英国、HU3 2JZ
        • Hull Royal Infirmary
      • Leeds、英国、LS7 4SA
        • Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital
      • Manchester、英国、M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle upon Tyne、英国、NE7 7DN
        • The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
      • Portsmouth、英国、PO6 3LY
        • Queen Alexandra Hospital
      • Salford、英国、M6 8HD
        • Shirley Caldwell
      • Southampton、英国、SO16 6YD
        • Southampton General Hospital
      • Staffordshire、英国、ST6 7AG
        • Haywood Hospital
      • Stamford、英国、PE9 1UA
        • Stamford and Rutland hospital
      • Wishaw、英国、ML2 0DP
        • Wishaw General
      • Amsterdam、荷兰、1105 AZ
        • Academisch Medisch Centrum Universiteit van Amsterdam
      • Enschede、荷兰、7500 KA
        • Medisch Spectrum Twente
      • Groningen、荷兰、9700 RB
        • Universitair Medisch Centrum Groningen
      • Helmond、荷兰、5707 HA
        • Elkerliek Ziekenhuis
      • A Coruña、西班牙、15006
        • Hosp Univ A Coruna
      • Algeciras / Cadiz、西班牙、11207
        • Hosp. Punta de Europa
      • Barcelona、西班牙、08036
        • Hosp Clinic de Barcelona
      • Barcelona、西班牙、8035
        • Hosp Univ Vall D Hebron
      • Bilbao、西班牙、48013
        • Hosp. Univ. de Basurto
      • Córdoba、西班牙、14004
        • Hosp Reina Sofia
      • Granada、西班牙、18016
        • Complejo hospitalario de Granada
      • Madrid、西班牙、28041
        • Hosp. Univ. 12 de Octubre
      • Madrid、西班牙、28905
        • Hosp. Univ. de Getafe
      • Oviedo、西班牙、33011
        • Hosp. Univ. Central de Asturias
      • Santiago de Compostela、西班牙、15706
        • Hosp. Clinico Univ. de Santiago
      • Seville、西班牙、41013
        • Hosp. Virgen Del Rocio
      • Buenos Aires、阿根廷、C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires、阿根廷、C1221ADC
        • Hospital J. M. Ramos Mejía
      • Buenos Aires、阿根廷、C1015ABO
        • OMI
      • Córdoba、阿根廷、5000
        • Hospital Cordoba
      • San Fernando、阿根廷、B1646
        • MR Medicina Reumatologica
      • Cheonan-si、韩国、31151
        • Soonchunhyang University Cheonan Hospital
      • Seongnam、韩国、13620
        • Seoul National University Bundang Hospital
      • Seoul、韩国、03080
        • Seoul National University Hospital
      • Seoul、韩国、07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.

描述

Inclusion Criteria:

Main study:

  • Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
  • Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
  • Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations

Substudy:

  • Must sign the substudy ICF allowing data collection in accordance with local requirements
  • Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
  • Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities

Exclusion Criteria:

Main study:

  • Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
  • Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)

Substudy:

  • Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
  • Unwilling or unable to comply with substudy assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Cohort 1: Guselkumab

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.

其他名称:
  • TREMFYA
Cohort 2: Interleukin-17 inhibitor (IL-17i)

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
大体时间:Up to 39 months

The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
大体时间:Up to 39 months

The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
大体时间:Baseline up to 39 months

Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet.

Baseline up to 39 months
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
大体时间:Baseline up to 39 months

The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm).

Baseline up to 39 months
Change from Baseline in Assessment of Dactylitis
大体时间:Baseline up to 39 months

The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented.

Baseline up to 39 months
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
大体时间:Baseline up to 39 months

The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right).

Baseline up to 39 months
Change from Baseline in Nail Involvement
大体时间:Baseline up to 39 months

Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes.

Baseline up to 39 months
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
大体时间:Baseline up to 39 months

The BSA score indicates the surface area of the participant's body effected by psoriasis.

Baseline up to 39 months
Change from Baseline in C-reactive Protein (CRP)
大体时间:Baseline up to 39 months

Change from baseline in CRP will be reported.

Baseline up to 39 months
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
大体时间:Baseline up to 39 months

Change from Baseline in MDA/VLDA will be reported.

Baseline up to 39 months
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
大体时间:Baseline up to 39 months

DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Baseline up to 39 months
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
大体时间:Up to 39 months

Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Up to 39 months
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
大体时间:Up to 39 months

Start and stop dates of all treatments and the sequence of treatment lines will be reported.

Up to 39 months
Percentage of Participants with Adverse Events (AEs)
大体时间:Up to 39 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 39 months
BSA PSO Skin Involvement
大体时间:Up to 39 months

The BSA score indicates the surface area of the participant's body affected by psoriasis.

Up to 39 months
Rheumatic Disease Comorbidity Index
大体时间:Up to 39 months

Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported.

Up to 39 months
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
大体时间:Baseline up to 6 months

FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain.

Baseline up to 6 months
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
大体时间:Baseline up to 39 months

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems.

Baseline up to 39 months
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
大体时间:Baseline up to 39 months

The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.

Baseline up to 39 months
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
大体时间:Baseline up to 39 months

PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline up to 39 months
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
大体时间:Baseline up to 39 months

The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week.

Baseline up to 39 months
Change from Baseline in Pain VAS Score
大体时间:Baseline up to 39 months

The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm).

Baseline up to 39 months
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
大体时间:Baseline up to 39 months

BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity.

Baseline up to 39 months
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
大体时间:Baseline up to 39 months

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value.

Baseline up to 39 months
Change from Baseline in Dermatology Life Quality Index (DLQI)
大体时间:Baseline up to 39 months

The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant.

Baseline up to 39 months
Change from Baseline in Patient Acceptable Symptom State (PASS)
大体时间:Baseline up to 39 months

The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being.

Baseline up to 39 months
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
大体时间:Baseline up to 39 months

The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

Baseline up to 39 months
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
大体时间:Baseline up to 39 months

TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication.

Baseline up to 39 months
Number of Participants Switching or Stopping Treatment
大体时间:Up to 39 months

Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported.

Up to 39 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Pharmaceutica N.V., Belgium Clinical Trial、Janssen Pharmaceutica N.V., Belgium

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年8月25日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年8月2日

研究注册日期

首次提交

2021年8月31日

首先提交符合 QC 标准的

2021年9月17日

首次发布 (实际的)

2021年9月20日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CR108938
  • CNTO1959PSA4001 (其他标识符:Janssen Research & Development, LLC)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅